sorrento therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical car-t therapies targeting solid tumors.
Company profile
Ticker
SRNEQ
Exchange
Website
CEO
Henry Ji
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
QUIKBYTE SOFTWARE INC
SEC CIK
Corporate docs
Subsidiaries
Concortis Biosystems, Corp. • Ark Animal Health, Inc. • TNK Therapeutics, Inc. • BioServ Corporation • Adnab, Inc. • ACEA Therapeutics, Inc. • Scilex Holding Company • Semnur Pharmaceuticals, Inc. • Scilex Pharmaceuticals Inc. • Levena Biopharma US, Inc. ...
IRS number
330344842
SRNEQ stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
7 Nov 23
8-K
Entry into a Material Definitive Agreement
3 Nov 23
8-K
Departure of Directors or Certain Officers
27 Oct 23
8-K
Entry into a Material Definitive Agreement
5 Oct 23
8-K
Entry into a Material Definitive Agreement
26 Sep 23
8-K
Other Events
12 Sep 23
8-K
Entry into a Material Definitive Agreement
28 Aug 23
8-K
Regulation FD Disclosure
21 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Entry into a Material Definitive Agreement
10 Aug 23
Latest ownership filings
SC 13G/A
Celularity Inc
5 Oct 23
4
Celularity Inc
5 Oct 23
SC 13D/A
Scilex Holding Co
26 Sep 23
4
Scilex Holding Co
25 Sep 23
SC 13D/A
Scilex Holding Co
14 Aug 23
4
Henry Ji
20 Mar 23
SC 13G/A
STATE STREET CORP
10 Mar 23
SC 13G/A
BlackRock Inc.
8 Mar 23
SC 13D/A
Scilex Holding Co
3 Mar 23
SC 13G
ICS OPPORTUNITIES, LTD.
17 Feb 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 69.75 mm | 69.75 mm | 69.75 mm | 69.75 mm | 69.75 mm | 69.75 mm |
Cash burn (monthly) | (no burn) | 49.67 k | 25.74 mm | 38.55 mm | 18.55 mm | 19.55 mm |
Cash used (since last report) | n/a | 444.23 k | 230.26 mm | 344.83 mm | 165.94 mm | 174.88 mm |
Cash remaining | n/a | 69.30 mm | -160.51 mm | -275.08 mm | -96.19 mm | -105.13 mm |
Runway (months of cash) | n/a | 1395.4 | -6.2 | -7.1 | -5.2 | -5.4 |
Institutional ownership, Q3 2023
8.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 16 |
Opened positions | 2 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 217.74 mm |
Total shares | 48.05 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ics Opportunities | 14.52 mm | $2.40 mm |
Xianjian Advanced Technology | 7.34 mm | $51.77 mm |
Famous Sino | 5.96 mm | $40.71 mm |
China In Shine Investment | 4.76 mm | $32.49 mm |
Ally Bridge Group Capital Partners II | 4.45 mm | $12.10 mm |
Hongguo International | 4.07 mm | $27.81 mm |
Asia Pacific MedTech | 3.55 mm | $24.22 mm |
Magnum Opus 2 International | 3.34 mm | $22.82 mm |
KLCM Advisors | 20.00 k | $1.88 mm |
Huntington National Bank | 15.00 k | $1.41 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Oct 23 | Sorrento Therapeutics | Class A Common Stock | Sell | Dispose S | No | No | 0 | 6,307,158 | 0.00 | 5,050,427 |
29 Sep 23 | Sorrento Therapeutics | Class A Common Stock | Sell | Dispose S | No | No | 0 | 9,064,539 | 0.00 | 11,357,585 |
21 Sep 23 | Sorrento Therapeutics | Common Stock | Sell | Dispose S | No | No | 0 | 60,068,585 | 0.00 | 1,917,210 |
21 Sep 23 | Sorrento Therapeutics | Warrants to Purchase Common Stock Common Stock | Sell | Dispose S | No | No | 11.5 | 4,490,617 | 51.64 mm | 0 |
17 Mar 23 | Ji Henry | Common Stock | Acquire X | Yes | No | 0.8027 | 19,500 | 15.65 k | 20,000 | |
17 Mar 23 | Ji Henry | Put Option (obligation to buy) Common Stock | Sale back to company | Dispose D | Yes | No | 0.8027 | 195 | 156.53 | 0 |
19 Jan 23 | Sorrento Therapeutics | Common Stock | Other | Dispose J | No | No | 0 | 73,740,795 | 0.00 | 61,985,795 |
15 Dec 22 | Ji Henry | Common Stock | Grant | Acquire A | No | No | 0 | 1,500,000 | 0.00 | 6,265,805 |